Horizon Discovery
Horizon Discovery, formerly of PerkinElmer, and now part of the Revvity family, drives the application of gene editing and gene modulation to enable world-leading academic institutes, pharmaceutical and biotechnology companies, as well as clinical diagnostic laboratories, to identify the genetic drivers behind human disease, develop and validate diagnostic workflows and deliver new therapies for precision medicine.
Latest Horizon Discovery Content
Product News
CN Bio Appoints Dr Paul Brooks as Chief Executive Officer
CN Bio has announced the appointment of Dr Paul Brooks, formerly the Company’s Chief Business Officer, to the position of CEO with immediate effect.
Product News
Medical Device Innovation Consortium Partners With PerkinElmer's Horizon Discovery To Improve Accuracy of Next Generation Sequencing-Based Cancer Diagnostics
The Medical Device Innovation Consortium has partnered with PerkinElmer's Horizon Discovery to develop and manufacture somatic reference samples to simplify and support the validation of next-generation sequencing-based cancer diagnostics.
Industry Insight
Moving Towards the Next Era in Rare Disease Therapeutics
In this two-part interview series, Technology Networks explores some of the reasons behind the difficulties diagnosing and treating rare diseases, and finds out more about recent developments to improve options for patients.
Industry Insight
Women in Science: Perspectives From Industry
In honor of International Day of Women and Girls in Science 2022, Technology Networks interviewed three women who have built successful careers within the scientific industry, to learn about their career paths and the reasons they chose to work in industry.
Advertisement
